Drug Profile

CU 05

Alternative Names: CU-05

Latest Information Update: 03 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CURACLE
Class Antineoplastics; Immunotherapies
Mechanism of Action AMIGO2 protein antagonists; Proto-oncogene protein c-akt inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

03 Jan 2024 CU 05 is still in research phase for Lung cancer in South Korea (PO) (Curacle pipeline; January 2024)
28 Oct 2023 No recent reports of development identified for research development in Lung-cancer in South Korea (PO)
04 Oct 2019 CU 05 is available for licensing in World as of 04 Oct 2019. http://www.curacle.com/en/overview/

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com